Weeks into CEO shakeup, Mirati bids adieu to a pair of C-suiters with KRAS drug filing around the corner
Mirati is on the cusp of emerging as the sole challenger against Amgen in the suddenly hot KRAS inhibitor market and thinks it has the man to take it across the finish line. But new leadership often means shakeups, and now two Mirati execs are being shown the door.
Mirati CMO Joseph Leveque and Daniel Faga, the biotech’s chief operating officer and principal financial officer, have both departed the company as it enters the homestretch for filing its KRAS drug adagrasib with the FDA, Mirati revealed in an SEC filing Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.